Large arrow graphic

inVentiv Health Selects Medidata Enroll®, Medidata’s eConsent Platform, to Accelerate Clinical Trials

inVentiv and Medidata Partner to Expand Use of Patient-Centered Technology to Better Connect Patients, Sites and Biopharmaceutical Clients

NEW YORK and BOSTON - June 26, 2017 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, and inVentiv Health, a leading biopharmaceutical professional services company, today announced a multi-year partnership to bring patient-centric technology and leading clinical trial expertise to the biopharmaceutical industry. The partnership will broaden the reach of Medidata’s industry-leading electronic informed consent (eConsent) technology, Medidata Enroll, to patients, sites and biopharmaceutical clients worldwide.

Medidata recently acquired Mytrus, Incorporated, an eClinical technology company specializing in eConsent and virtual trials. inVentiv, an early adopter of eConsent technology, invested in Mytrus in 2013. inVentiv and Medidata will now partner to provide their joint customers with best-in-class training, services and support around the use of the advanced eConsent platform, Medidata Enroll.

“As clinical development evolves toward a more patient-centric, technologically-savvy model, the use of eConsent is becoming increasingly relevant,” said Rachel Stahler, Chief Information Officer, inVentiv Health. “By pairing Medidata’s industry-leading technology platform with inVentiv’s vast clinical trial and patient engagement capabilities, we can expedite study start-up and transform the trial process for patients and sites. This partnership reinforces our commitment to delivering better systems, rich data and actionable insights to accelerate our clients’ abilities to deliver important therapies to market.”

A critical component to any clinical trial, electronic informed consent provides patients with clear, visually compelling information about trial participation in an easily accessible digital format. This modernized process facilitates dialogue between physician and patient, and may increase patient engagement in a trial. Medidata Enroll also provides advanced visualization and analytics for trial sponsors and monitors, and streamlines site workflow and data capture.

“CROs are critical partners in delivering transformative technology like eConsent to our clients in clinical development,” said Kara Dennis, Medidata’s managing director of mHealth. “We’re thrilled to see inVentiv Health show leadership in this area by broadly adopting Medidata Enroll across its clinical development programs. Medidata is committed to designing, building and supporting patient-centric tools to capture important data and facilitate meaningful dialogue between researchers and patients, and we look forward to combining our technology with inVentiv’s globally-recognized expertise to pioneer a more efficient consent process.”

Together, Medidata and inVentiv Health are facilitating an updated trial experience, enabling biopharmaceutical companies, sites and patients to make use of Medidata’s intuitive technology to better support trial operations and virtual patient engagement. With inVentiv Health’s ability to support clients in 90 countries—having developed or commercialized 82% of novel new drugs approved by the FDA in the last five years—the strategic partnership is also expanding Medidata’s reach to sponsors all over the globe.

To learn more about how inVentiv Health experts can help you, please contact us by clicking here.

Contact Us


inVentiv Health has been made aware of an internet scam targeting job seekers who have posted their resumes on job posting websites. Scammers are contacting applicants via email and purporting to represent inVentiv Health. Many of these scammers are using Gmail accounts and Google Hangouts to communicate with applicants. All correspondence with us comes from an internal employee with a valid @inventivhealth.com email address. Anyone who suspects they have been solicited in this scam should contact the FBI at ic3.gov.